Concurrent Treatment With CAR T-Cells, Ibrutinib Leads to Marrow Clearance in Resistant CLL – Targeted Oncology
Targeted Oncology |
Concurrent Treatment With CAR T-Cells, Ibrutinib Leads to Marrow Clearance in Resistant CLL
Targeted Oncology The preliminary results from the ongoing study continued the unfolding success story of chimeric antigen receptor (CAR) T-cell therapy in the treatment of hematologic malignancies. Acknowledging that CAR T-cell therapy has achieved high response rates … |
